Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access to a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain

Contributed by: Business Wire

Logo

Tags

Health

Other Health

Clinical Trials

General Health

Pharmaceutical

Biotechnology

Augurex Announces UKCA Authorization for SPINEstat

More Like This

Augurex Life Sciences Granted FDA Breakthrough Designation for SPINEstat®, its First-in-Class Diagnostic Test for Axial Spondyloarthritis

Augurex Announces UK Conformity Assessed (UKCA) Authorization for JOINTstat®, Expanding Access to Cutting-Edge Rheumatoid Arthritis Testing in Great Britain

Augurex Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

PR Newswire associated0

MosaiQ AiPlex® Vasculitis assay now available for clinical use in the European Union and other CE mark accepting countries

PR Newswire associated0

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research

PR Newswire associated0

AliveDx announces U.S. Food and Drug Administration (FDA) 510(k) submission for its MosaiQ AiPlex® Vasculitis (VAS) assay.

PR Newswire associated0

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study